1.00 Expanding Beyond Bispecific & T Cells to Address Tumor Heterogeneity
Time: 1:00 pm
day: Workshop C
Details:
Currently the only approved cell engagers are designed exclusively for T cells. Natural killer (NK) cells are being leveraged in the clinic due to their safety profile and their ability to mediate tumor killing without prior priming. However, lack of antigen-specific targeting, decreased numbers, and suppressive signals derived from the tumor microenvironment (TME) can impact NK cell efficacy.
- Bypass these issue, we designed novel tri-specific killer engager (TriKE®) molecule that consists of three parts: an arm that engages with CD16, a potent activating receptor on NK cells, an arm that binds to tumor antigens express (CD33, B7H3, CD19, PSMA, TEM8, etc), and an interleukin (IL)-15 moiety that is essential for NK cell survival, proliferation, priming and motility.
- Using this platform, we have been able to target a variety of hematologic malignancies and solid tumors. This workshop will focus on these molecules and NK cell engagers and discuss their features and advantages.
